HS-10370
- Generic Name
- HS-10370
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid TumorsColorectal CancerNon-Small Cell Lung Cancer
- Interventions
- Drug: Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 762
- Registration Number
- NCT06963502
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
🇨🇳Sun Yat-sen University Cancer Center, Shanghai, China
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Non-Small Cell Lung CancerAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06594874
- Locations
- 🇨🇳
Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, China
Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 176
- Registration Number
- NCT05367778
- Locations
- 🇨🇳
Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath